The hemophilia drug business that Biogen Inc. plans to spin off as a separate company early next year will be named Bioverativ.

Bioverativ will market Biogen’s two hemophilia drugs, Eloctate and Alprolix -- both approved in 2014 by the FDA -- and develop additional treatments for blood disorders.

The new company, based in the Boston area, will trade on the Nasdaq under the symbol BIVV.

Read the Boston Globe coverage